CYTK RSI Chart
Last 7 days
3.4%
Last 30 days
-12.3%
Last 90 days
51.2%
Trailing 12 Months
83.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 98.1M | 10.0M | 7.8M | 7.5M |
2022 | 76.5M | 82.5M | 88.5M | 94.6M |
2021 | 58.6M | 57.8M | 21.6M | 70.4M |
2020 | 22.2M | 18.7M | 54.3M | 55.8M |
2019 | 34.7M | 35.6M | 31.0M | 26.9M |
2018 | 17.9M | 22.4M | 27.0M | 31.5M |
2017 | 102.1M | 99.4M | 46.5M | 13.4M |
2016 | 32.7M | 31.9M | 83.0M | 106.4M |
2015 | 43.4M | 42.1M | 40.7M | 28.7M |
2014 | 37.8M | 44.6M | 49.5M | 46.9M |
2013 | 6.6M | 5.7M | 8.5M | 30.6M |
2012 | 5.1M | 5.8M | 6.1M | 7.6M |
2011 | 2.9M | 3.3M | 4.3M | 4.0M |
2010 | 0 | 55.2M | 28.9M | 2.6M |
2009 | 0 | 0 | 0 | 81.5M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 14, 2024 | callos andrew | acquired | - | - | 16,941 | evp, chief commercial officer |
Mar 14, 2024 | blum robert i | acquired | - | - | 61,490 | president & ceo |
Mar 14, 2024 | malik fady ibraham | acquired | - | - | 42,666 | evp research & development |
Mar 14, 2024 | wong robert | acquired | - | - | 4,079 | vp, chief accounting officer |
Mar 06, 2024 | malik fady ibraham | sold (taxes) | -542,330 | 66.88 | -8,109 | evp research & development |
Mar 06, 2024 | blum robert i | sold (taxes) | -1,118,570 | 66.88 | -16,725 | president & ceo |
Mar 06, 2024 | callos andrew | sold (taxes) | -341,289 | 66.88 | -5,103 | evp, chief commercial officer |
Mar 06, 2024 | wong robert | sold (taxes) | -57,316 | 66.88 | -857 | vp, chief accounting officer |
Mar 05, 2024 | malik fady ibraham | acquired | 190,789 | 6.67 | 28,604 | evp research & development |
Mar 05, 2024 | malik fady ibraham | sold | -2,202,610 | 67.5563 | -32,604 | evp research & development |
Which funds bought or sold CYTK recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | reduced | -7.01 | 355,199 | 572,408 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 2.55 | 603,302,000 | 919,800,000 | 0.02% |
Mar 05, 2024 | Fisher Asset Management, LLC | new | - | 44,754,500 | 44,754,500 | 0.02% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 129 | 115,262,000 | 136,163,000 | 0.01% |
Mar 01, 2024 | READYSTATE ASSET MANAGEMENT LP | new | - | 4,700,490 | 4,700,490 | 0.16% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.65 | 2,740,260 | 4,249,640 | 0.02% |
Feb 26, 2024 | Virtu Financial LLC | new | - | 3,905,000 | 3,905,000 | 0.31% |
Feb 26, 2024 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | reduced | -5.46 | 2,859,000 | 4,562,000 | 0.04% |
Feb 26, 2024 | PERCEPTIVE ADVISORS LLC | new | - | 2,531,170 | 2,531,170 | 0.06% |
Feb 26, 2024 | Neo Ivy Capital Management | sold off | -100 | -470,000 | - | -% |
Unveiling Cytokinetics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cytokinetics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Cytokinetics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 342.3% | 2.00 | 0.00 | 1.00 | 5.00 | 2.00 | 3.00 | 89.00 | 72.00 | 56.00 | 5.00 | 3.00 | 7.00 | 7.00 | 42.00 | 4.00 | 4.00 | 5.00 | 6.00 | 7.00 | 8.00 | 9.00 |
Operating Expenses | 5.3% | 129 | 123 | 123 | 129 | 129 | 111 | 100 | 79.00 | 77.00 | 75.00 | 58.00 | 47.00 | 43.00 | 37.00 | 36.00 | 34.00 | 29.00 | 30.00 | 34.00 | 33.00 | 31.00 |
S&GA Expenses | 10.0% | 44.00 | 40.00 | 40.00 | 50.00 | 54.00 | 48.00 | 43.00 | 33.00 | 34.00 | 26.00 | 21.00 | 16.00 | 14.00 | 12.00 | 14.00 | 12.00 | 11.00 | 10.00 | 10.00 | 9.00 | 7.00 |
R&D Expenses | 3.0% | 85.00 | 83.00 | 83.00 | 79.00 | 75.00 | 63.00 | 57.00 | 46.00 | 43.00 | 48.00 | 36.00 | 32.00 | 29.00 | 24.00 | 22.00 | 22.00 | 18.00 | 20.00 | 24.00 | 24.00 | 24.00 |
EBITDA Margin | 16.7% | 5.74* | 4.92* | 3.79* | 0.34* | 0.30* | 0.28* | 0.25* | 0.28* | 0.31* | 0.99* | 0.37* | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | 0.4% | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 1.00 | 1.00 | 1.00 | 1.00 |
EBT Margin | 3.8% | 0.40* | 0.39* | 0.31* | 0.03* | 0.03* | 0.03* | 0.04* | 0.04* | 0.04* | 0.14* | 0.05* | - | - | - | - | - | - | - | - | - | - |
Net Income | -5.8% | -136 | -129 | -128 | -131 | -137 | -142 | -19.82 | -89.44 | -30.57 | -76.09 | -61.55 | -47.10 | -43.93 | -3.17 | -40.78 | -39.40 | -30.64 | -29.57 | -32.11 | -29.37 | -26.47 |
Net Income Margin | -3.7% | -69.89* | -67.40* | -54.22* | -4.39* | -4.11* | -3.19* | -2.62* | -3.37* | -3.06* | -10.61* | -2.69* | -2.31* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 23.1% | -74.11 | -96.42 | -122 | -122 | -101 | -90.37 | -91.33 | -27.75 | -62.49 | -54.47 | -38.29 | -36.15 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 11.3% | 824 | 741 | 780 | 890 | 1,015 | 1,076 | 772 | 856 | 841 | 828 | 564 | 577 | 534 | 474 | 232 | 257 | 290 | 187 | 198 | 199 | 211 |
Current Assets | 11.9% | 628 | 561 | 587 | 681 | 795 | 884 | 602 | 624 | 536 | 495 | 364 | 433 | 474 | 418 | 219 | 226 | 234 | 177 | 185 | 186 | 208 |
Cash Equivalents | 13.4% | 113 | 100 | 69.00 | 102 | 66.00 | 106 | 94.00 | 115 | 113 | 91.00 | 37.00 | 45.00 | 83.00 | 201 | 61.00 | 50.00 | 36.00 | 40.00 | 34.00 | 39.00 | 42.00 |
Net PPE | -9.1% | 69.00 | 76.00 | 77.00 | 79.00 | 80.00 | 80.00 | 79.00 | 76.00 | 73.00 | 54.00 | 37.00 | 23.00 | 13.00 | 8.00 | 6.00 | 5.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 |
Liabilities | 2.6% | 1,211 | 1,179 | 1,113 | 1,119 | 1,123 | 1,092 | 660 | 740 | 597 | 579 | 548 | 509 | 420 | 325 | 311 | 302 | 301 | 207 | 203 | 195 | 185 |
Current Liabilities | 32.1% | 103 | 78.00 | 66.00 | 75.00 | 85.00 | 76.00 | 67.00 | 67.00 | 72.00 | 81.00 | 62.00 | 36.00 | 31.00 | 28.00 | 23.00 | 21.00 | 26.00 | 22.00 | 22.00 | 26.00 | 22.00 |
Long Term Debt | -4.1% | 58.00 | 61.00 | 62.00 | 64.00 | 64.00 | 64.00 | 62.00 | 61.00 | 47.00 | 30.00 | 36.00 | 41.00 | 46.00 | 46.00 | 46.00 | 45.00 | 45.00 | 45.00 | 44.00 | 36.00 | 40.00 |
LT Debt, Current | - | 10.00 | - | - | - | 1.00 | - | - | - | - | 17.00 | 11.00 | 6.00 | - | - | - | - | - | - | - | 6.00 | 3.00 |
LT Debt, Non Current | -4.1% | 58.00 | 61.00 | 62.00 | 64.00 | 64.00 | 64.00 | 62.00 | 61.00 | 47.00 | 30.00 | 36.00 | 41.00 | 46.00 | 46.00 | 46.00 | 45.00 | 45.00 | 45.00 | 44.00 | 36.00 | 40.00 |
Shareholder's Equity | -Infinity% | -386 | - | - | - | -107 | - | 111 | 116 | 244 | 249 | 16.00 | 68.00 | 113 | 150 | - | - | - | - | - | 3.00 | 26.00 |
Retained Earnings | -5.6% | -2,112 | -2,000 | -1,800 | -1,700 | -1,585 | -1,448 | -1,306 | -1,286 | -1,207 | -1,177 | -1,101 | -1,039 | -992 | -948 | -945 | -904 | -865 | -834 | -804 | -772 | -743 |
Additional Paid-In Capital | 12.3% | 1,726 | 1,537 | 1,514 | 1,490 | 1,482 | 1,438 | 1,422 | 1,406 | 1,452 | 1,426 | 1,117 | 1,107 | 1,105 | 1,097 | 866 | 857 | 853 | 814 | 799 | 775 | 769 |
Shares Outstanding | - | 102 | - | - | - | 95.00 | - | - | - | 85.00 | - | - | - | 71.00 | - | - | - | 59.00 | - | - | - | - |
Float | - | - | - | 2,000 | - | - | - | 2,000 | - | - | - | 1,443 | - | - | - | 1,413 | - | - | - | 653 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 23.0% | -74.03 | -96.20 | -121 | -122 | -98.19 | -84.04 | -90.47 | -26.81 | -44.74 | -38.77 | -29.50 | -29.52 | 52.00 | 14.00 | -27.44 | -30.13 | -19.05 | -20.27 | -24.68 | -26.91 | -12.33 |
Share Based Compensation | 4.1% | 19.00 | 19.00 | 19.00 | 15.00 | 13.00 | 13.00 | 12.00 | 9.00 | 7.00 | 8.00 | 7.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 | 2.00 | - |
Cashflow From Investing | -211.5% | -81.41 | 73.00 | 82.00 | 165 | 29.00 | -292 | 65.00 | -64.28 | 47.00 | -208 | 19.00 | -5.28 | -173 | -101 | 35.00 | 43.00 | -105 | 14.00 | -2.77 | 20.00 | 27.00 |
Cashflow From Financing | 211.3% | 169 | 54.00 | 5.00 | -7.18 | 30.00 | 389 | 3.00 | 94.00 | 20.00 | 301 | 3.00 | -3.60 | 4.00 | 226 | 4.00 | -0.01 | 121 | 12.00 | 22.00 | 4.00 | 0.00 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Total revenues | $ 7,530 | $ 94,588 | $ 70,428 |
Operating expenses: | |||
Research and development | 330,123 | 240,813 | 159,938 |
General and administrative | 173,612 | 177,977 | 96,803 |
Total operating expenses | 503,735 | 418,790 | 256,741 |
Operating loss | (496,205) | (324,202) | (186,313) |
Interest expense | (28,306) | (19,414) | (16,440) |
Loss on extinguishment of debt | 0 | (24,939) | 0 |
Non-cash interest expense on liabilities related to revenue participation right purchase agreements | (29,362) | (31,742) | (12,892) |
Interest and other income, net | 27,629 | 11,342 | 331 |
Net loss | $ (526,244) | $ (388,955) | $ (215,314) |
Net loss per share - basic | $ (5.45) | $ (4.33) | $ (2.8) |
Net loss per share - diluted | $ (5.45) | $ (4.33) | $ (2.8) |
Weighted-average number of shares used in computing net loss per share - basic | 96,524 | 89,825 | 76,886 |
Weighted-average number of shares used in computing net loss per share - diluted | 96,524 | 89,825 | 76,886 |
Other comprehensive gain (loss): | |||
Unrealized gain (loss) on available-for-sale securities, net | $ 3,600 | $ (2,721) | $ (1,018) |
Foreign currency translation adjustments | (20) | 0 | 0 |
Comprehensive loss | (522,664) | (391,676) | (216,332) |
Research and Development Revenues [Member] | |||
Revenues: | |||
Total revenues | 4,030 | 6,588 | 10,572 |
License Revenues [Member] | |||
Revenues: | |||
Total revenues | 0 | 0 | 54,856 |
Milestone Revenues [Member] | |||
Revenues: | |||
Total revenues | 3,500 | 1,000 | 5,000 |
Realization of Revenue Participation Right Purchase Agreement [Member] | |||
Revenues: | |||
Total revenues | $ 0 | $ 87,000 | $ 0 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 113,024 | $ 65,582 |
Short-term investments | 501,800 | 716,995 |
Accounts receivable | 1,283 | 147 |
Prepaid expenses and other current assets | 11,944 | 12,462 |
Total current assets | 628,051 | 795,186 |
Long-term investments | 40,534 | 46,708 |
Property and equipment, net | 68,748 | 80,453 |
Operating lease right-of-use assets | 78,987 | 82,737 |
Other assets | 7,996 | 9,691 |
Total assets | 824,316 | 1,014,775 |
Current liabilities: | ||
Accounts payable | 21,507 | 25,611 |
Accrued liabilities | 42,641 | 44,096 |
Short-term operating lease liabilities | 17,891 | 12,829 |
Current portion of long-term debt | 10,080 | 958 |
Other current liabilities | 10,559 | 1,123 |
Total current liabilities | 102,678 | 84,617 |
Term loan, net | 58,384 | 63,810 |
Convertible notes, net | 548,989 | 545,808 |
Liabilities related to revenue participation right purchase agreements, net | 379,975 | 300,501 |
Long-term operating lease liabilities | 120,427 | 126,895 |
Other non-current liabilities | 186 | 1,044 |
Total liabilities | 1,210,639 | 1,122,675 |
Commitments and contingencies | ||
Stockholders' deficit: | ||
Preferred stock, $0.001 par value: Authorized: 10,000,000 shares; Issued and outstanding: none | 0 | 0 |
Common stock, $0.001 par value: Authorized: 163,000,000 shares; Issued and outstanding: 101,637,922 shares at December 31, 2023 and 94,833,975 shares at December 31, 2022 | 102 | 94 |
Additional paid-in capital | 1,725,823 | 1,481,590 |
Accumulated other comprehensive loss | (10) | (3,590) |
Accumulated deficit | (2,112,238) | (1,585,994) |
Total stockholders' deficit | (386,323) | (107,900) |
Total liabilities and stockholders' deficit | $ 824,316 | $ 1,014,775 |